nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—MAP3K9—epithelium—salivary gland cancer	0.00866	0.0299	CbGeAlD
Pazopanib—RIOK2—parotid gland—salivary gland cancer	0.00613	0.0212	CbGeAlD
Pazopanib—ITK—lymphoid tissue—salivary gland cancer	0.0055	0.019	CbGeAlD
Pazopanib—LYN—connective tissue—salivary gland cancer	0.00542	0.0187	CbGeAlD
Pazopanib—PI4KB—parotid gland—salivary gland cancer	0.00542	0.0187	CbGeAlD
Pazopanib—FGFR3—connective tissue—salivary gland cancer	0.0054	0.0186	CbGeAlD
Pazopanib—FGF1—neck—salivary gland cancer	0.00522	0.018	CbGeAlD
Pazopanib—PI4KB—saliva-secreting gland—salivary gland cancer	0.00519	0.0179	CbGeAlD
Pazopanib—FGFR3—epithelium—salivary gland cancer	0.00512	0.0177	CbGeAlD
Pazopanib—BMPR1B—epithelium—salivary gland cancer	0.00507	0.0175	CbGeAlD
Pazopanib—FGFR2—neck—salivary gland cancer	0.00493	0.017	CbGeAlD
Pazopanib—PIP4K2C—parotid gland—salivary gland cancer	0.00476	0.0164	CbGeAlD
Pazopanib—SH2B3—lymphoid tissue—salivary gland cancer	0.00471	0.0163	CbGeAlD
Pazopanib—FLT1—neck—salivary gland cancer	0.00457	0.0158	CbGeAlD
Pazopanib—PIP4K2C—saliva-secreting gland—salivary gland cancer	0.00456	0.0157	CbGeAlD
Pazopanib—PLK4—lymphoid tissue—salivary gland cancer	0.00424	0.0147	CbGeAlD
Pazopanib—STK16—lymphoid tissue—salivary gland cancer	0.00401	0.0138	CbGeAlD
Pazopanib—FLT4—epithelium—salivary gland cancer	0.004	0.0138	CbGeAlD
Pazopanib—MAP3K2—connective tissue—salivary gland cancer	0.00397	0.0137	CbGeAlD
Pazopanib—LYN—lymphoid tissue—salivary gland cancer	0.00397	0.0137	CbGeAlD
Pazopanib—KDR—neck—salivary gland cancer	0.00386	0.0133	CbGeAlD
Pazopanib—FGFR2—saliva-secreting gland—salivary gland cancer	0.00384	0.0133	CbGeAlD
Pazopanib—MAP3K9—lymph node—salivary gland cancer	0.00376	0.013	CbGeAlD
Pazopanib—FGF1—connective tissue—salivary gland cancer	0.00374	0.0129	CbGeAlD
Pazopanib—FLT1—parotid gland—salivary gland cancer	0.00372	0.0128	CbGeAlD
Pazopanib—EPHB6—parotid gland—salivary gland cancer	0.00368	0.0127	CbGeAlD
Pazopanib—FLT1—saliva-secreting gland—salivary gland cancer	0.00356	0.0123	CbGeAlD
Pazopanib—FGF1—epithelium—salivary gland cancer	0.00355	0.0123	CbGeAlD
Pazopanib—FGFR2—connective tissue—salivary gland cancer	0.00353	0.0122	CbGeAlD
Pazopanib—EPHB6—saliva-secreting gland—salivary gland cancer	0.00352	0.0122	CbGeAlD
Pazopanib—TAOK3—parotid gland—salivary gland cancer	0.00351	0.0121	CbGeAlD
Pazopanib—LIMK2—lymphoid tissue—salivary gland cancer	0.00343	0.0118	CbGeAlD
Pazopanib—KIT—neck—salivary gland cancer	0.00342	0.0118	CbGeAlD
Pazopanib—TAOK3—saliva-secreting gland—salivary gland cancer	0.00336	0.0116	CbGeAlD
Pazopanib—FGFR2—epithelium—salivary gland cancer	0.00335	0.0116	CbGeAlD
Pazopanib—PDGFRB—neck—salivary gland cancer	0.00334	0.0115	CbGeAlD
Pazopanib—FLT1—connective tissue—salivary gland cancer	0.00327	0.0113	CbGeAlD
Pazopanib—MAP2K5—parotid gland—salivary gland cancer	0.00314	0.0109	CbGeAlD
Pazopanib—KDR—parotid gland—salivary gland cancer	0.00314	0.0109	CbGeAlD
Pazopanib—FLT1—epithelium—salivary gland cancer	0.00311	0.0107	CbGeAlD
Pazopanib—ITK—lymph node—salivary gland cancer	0.0031	0.0107	CbGeAlD
Pazopanib—TAOK3—connective tissue—salivary gland cancer	0.00309	0.0107	CbGeAlD
Pazopanib—FLT4—lymphoid tissue—salivary gland cancer	0.00308	0.0106	CbGeAlD
Pazopanib—PDGFRA—connective tissue—salivary gland cancer	0.00307	0.0106	CbGeAlD
Pazopanib—KDR—saliva-secreting gland—salivary gland cancer	0.00301	0.0104	CbGeAlD
Pazopanib—MAP2K5—saliva-secreting gland—salivary gland cancer	0.00301	0.0104	CbGeAlD
Pazopanib—MAP3K2—lymphoid tissue—salivary gland cancer	0.0029	0.01	CbGeAlD
Pazopanib—TAOK1—lymph node—salivary gland cancer	0.00282	0.00976	CbGeAlD
Pazopanib—KIT—parotid gland—salivary gland cancer	0.00279	0.00962	CbGeAlD
Pazopanib—KDR—connective tissue—salivary gland cancer	0.00277	0.00956	CbGeAlD
Pazopanib—FGF1—lymphoid tissue—salivary gland cancer	0.00273	0.00944	CbGeAlD
Pazopanib—PDGFRB—parotid gland—salivary gland cancer	0.00272	0.0094	CbGeAlD
Pazopanib—CSF1R—connective tissue—salivary gland cancer	0.0027	0.00933	CbGeAlD
Pazopanib—KIT—saliva-secreting gland—salivary gland cancer	0.00267	0.00922	CbGeAlD
Pazopanib—SH2B3—lymph node—salivary gland cancer	0.00266	0.00918	CbGeAlD
Pazopanib—KDR—epithelium—salivary gland cancer	0.00263	0.00907	CbGeAlD
Pazopanib—AURKC—lymph node—salivary gland cancer	0.00262	0.00904	CbGeAlD
Pazopanib—PDGFRB—saliva-secreting gland—salivary gland cancer	0.00261	0.009	CbGeAlD
Pazopanib—KIT—connective tissue—salivary gland cancer	0.00245	0.00847	CbGeAlD
Pazopanib—PDGFRB—connective tissue—salivary gland cancer	0.0024	0.00827	CbGeAlD
Pazopanib—PLK4—lymph node—salivary gland cancer	0.00239	0.00827	CbGeAlD
Pazopanib—FLT1—lymphoid tissue—salivary gland cancer	0.00239	0.00827	CbGeAlD
Pazopanib—KIT—epithelium—salivary gland cancer	0.00233	0.00804	CbGeAlD
Pazopanib—PDGFRB—epithelium—salivary gland cancer	0.00227	0.00785	CbGeAlD
Pazopanib—STK10—lymphoid tissue—salivary gland cancer	0.00227	0.00783	CbGeAlD
Pazopanib—STK16—lymph node—salivary gland cancer	0.00226	0.00781	CbGeAlD
Pazopanib—TAOK3—lymphoid tissue—salivary gland cancer	0.00226	0.0078	CbGeAlD
Pazopanib—PDGFRA—lymphoid tissue—salivary gland cancer	0.00224	0.00775	CbGeAlD
Pazopanib—RIOK2—lymph node—salivary gland cancer	0.00223	0.00769	CbGeAlD
Pazopanib—BMPR1B—lymph node—salivary gland cancer	0.0022	0.00761	CbGeAlD
Pazopanib—KDR—lymphoid tissue—salivary gland cancer	0.00202	0.00699	CbGeAlD
Pazopanib—STK36—lymph node—salivary gland cancer	0.002	0.00691	CbGeAlD
Pazopanib—CSF1R—lymphoid tissue—salivary gland cancer	0.00197	0.00682	CbGeAlD
Pazopanib—PI4KB—lymph node—salivary gland cancer	0.00197	0.0068	CbGeAlD
Pazopanib—LIMK2—lymph node—salivary gland cancer	0.00193	0.00668	CbGeAlD
Pazopanib—KIT—lymphoid tissue—salivary gland cancer	0.00179	0.00619	CbGeAlD
Pazopanib—PDGFRB—lymphoid tissue—salivary gland cancer	0.00175	0.00605	CbGeAlD
Pazopanib—FLT4—lymph node—salivary gland cancer	0.00174	0.006	CbGeAlD
Pazopanib—PIP4K2C—lymph node—salivary gland cancer	0.00173	0.00597	CbGeAlD
Pazopanib—FGFR1—lymph node—salivary gland cancer	0.00171	0.00592	CbGeAlD
Pazopanib—MAP3K2—lymph node—salivary gland cancer	0.00164	0.00566	CbGeAlD
Pazopanib—FGF1—lymph node—salivary gland cancer	0.00154	0.00533	CbGeAlD
Pazopanib—LCK—lymph node—salivary gland cancer	0.00153	0.0053	CbGeAlD
Pazopanib—ABCG2—parotid gland—salivary gland cancer	0.00153	0.00528	CbGeAlD
Pazopanib—ABCG2—saliva-secreting gland—salivary gland cancer	0.00147	0.00506	CbGeAlD
Pazopanib—FLT1—lymph node—salivary gland cancer	0.00135	0.00466	CbGeAlD
Pazopanib—EPHB6—lymph node—salivary gland cancer	0.00133	0.00461	CbGeAlD
Pazopanib—STK10—lymph node—salivary gland cancer	0.00128	0.00442	CbGeAlD
Pazopanib—TAOK3—lymph node—salivary gland cancer	0.00127	0.0044	CbGeAlD
Pazopanib—PDGFRA—lymph node—salivary gland cancer	0.00127	0.00437	CbGeAlD
Pazopanib—KDR—lymph node—salivary gland cancer	0.00114	0.00394	CbGeAlD
Pazopanib—MAP2K5—lymph node—salivary gland cancer	0.00114	0.00394	CbGeAlD
Pazopanib—CSF1R—lymph node—salivary gland cancer	0.00111	0.00385	CbGeAlD
Pazopanib—KIT—lymph node—salivary gland cancer	0.00101	0.00349	CbGeAlD
Pazopanib—PDGFRB—lymph node—salivary gland cancer	0.000988	0.00341	CbGeAlD
Pazopanib—ABCB1—epithelium—salivary gland cancer	0.00063	0.00218	CbGeAlD
Pazopanib—ABCG2—lymph node—salivary gland cancer	0.000555	0.00192	CbGeAlD
Pazopanib—ABCB1—lymphoid tissue—salivary gland cancer	0.000485	0.00168	CbGeAlD
Pazopanib—ABCB1—lymph node—salivary gland cancer	0.000274	0.000946	CbGeAlD
Pazopanib—FGFR1—Innate Immune System—PIK3CA—salivary gland cancer	2.06e-05	2.91e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NUP62—salivary gland cancer	2.06e-05	2.9e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—PIK3CA—salivary gland cancer	2.06e-05	2.9e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—salivary gland cancer	2.06e-05	2.9e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HRAS—salivary gland cancer	2.05e-05	2.88e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—VCAN—salivary gland cancer	2.05e-05	2.88e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PTEN—salivary gland cancer	2.04e-05	2.87e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—PTEN—salivary gland cancer	2.03e-05	2.85e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—PIK3CA—salivary gland cancer	2.02e-05	2.84e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—HRAS—salivary gland cancer	2.01e-05	2.83e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—EP300—salivary gland cancer	2.01e-05	2.83e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CREBBP—salivary gland cancer	2e-05	2.82e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ST3GAL4—salivary gland cancer	1.99e-05	2.8e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—PIK3CA—salivary gland cancer	1.98e-05	2.79e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CREBBP—salivary gland cancer	1.98e-05	2.79e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—PIK3CA—salivary gland cancer	1.98e-05	2.78e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—HRAS—salivary gland cancer	1.97e-05	2.77e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HRAS—salivary gland cancer	1.97e-05	2.77e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PYGB—salivary gland cancer	1.96e-05	2.76e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—salivary gland cancer	1.95e-05	2.75e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—EP300—salivary gland cancer	1.95e-05	2.74e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HRAS—salivary gland cancer	1.93e-05	2.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HRAS—salivary gland cancer	1.91e-05	2.69e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HRAS—salivary gland cancer	1.91e-05	2.68e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—HRAS—salivary gland cancer	1.9e-05	2.68e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	1.89e-05	2.66e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—PIK3CA—salivary gland cancer	1.88e-05	2.64e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAP2K2—salivary gland cancer	1.87e-05	2.63e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—HRAS—salivary gland cancer	1.87e-05	2.63e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—PIK3CA—salivary gland cancer	1.86e-05	2.61e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FOXO3—salivary gland cancer	1.83e-05	2.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HRAS—salivary gland cancer	1.83e-05	2.58e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HRAS—salivary gland cancer	1.83e-05	2.58e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—PTEN—salivary gland cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAP2K2—salivary gland cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NOTCH1—salivary gland cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—PIK3CA—salivary gland cancer	1.82e-05	2.56e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AQP1—salivary gland cancer	1.81e-05	2.55e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NUP62—salivary gland cancer	1.8e-05	2.53e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	1.8e-05	2.53e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—PTEN—salivary gland cancer	1.8e-05	2.53e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NOTCH1—salivary gland cancer	1.79e-05	2.52e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—VCAN—salivary gland cancer	1.78e-05	2.51e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—PIK3CA—salivary gland cancer	1.78e-05	2.51e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CCND1—salivary gland cancer	1.78e-05	2.51e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NOTCH1—salivary gland cancer	1.75e-05	2.47e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—PIK3CA—salivary gland cancer	1.74e-05	2.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EP300—salivary gland cancer	1.74e-05	2.45e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HRAS—salivary gland cancer	1.74e-05	2.44e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—PIK3CA—salivary gland cancer	1.73e-05	2.44e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CREBBP—salivary gland cancer	1.72e-05	2.42e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PTEN—salivary gland cancer	1.72e-05	2.42e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HRAS—salivary gland cancer	1.72e-05	2.42e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EP300—salivary gland cancer	1.71e-05	2.41e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CDH1—salivary gland cancer	1.71e-05	2.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PTEN—salivary gland cancer	1.7e-05	2.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NOTCH1—salivary gland cancer	1.7e-05	2.4e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PTEN—salivary gland cancer	1.7e-05	2.39e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NOTCH1—salivary gland cancer	1.7e-05	2.39e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NUP62—salivary gland cancer	1.69e-05	2.38e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PTEN—salivary gland cancer	1.69e-05	2.38e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—VCAN—salivary gland cancer	1.68e-05	2.37e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HRAS—salivary gland cancer	1.68e-05	2.37e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PTEN—salivary gland cancer	1.66e-05	2.33e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CREBBP—salivary gland cancer	1.66e-05	2.33e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—PIK3CA—salivary gland cancer	1.65e-05	2.33e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HRAS—salivary gland cancer	1.65e-05	2.32e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EP300—salivary gland cancer	1.64e-05	2.31e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CREBBP—salivary gland cancer	1.63e-05	2.29e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EP300—salivary gland cancer	1.63e-05	2.29e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EP300—salivary gland cancer	1.62e-05	2.28e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HRAS—salivary gland cancer	1.61e-05	2.27e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EP300—salivary gland cancer	1.61e-05	2.27e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HRAS—salivary gland cancer	1.6e-05	2.26e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—salivary gland cancer	1.6e-05	2.25e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	1.6e-05	2.25e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CCND1—salivary gland cancer	1.59e-05	2.24e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CREBBP—salivary gland cancer	1.59e-05	2.24e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—PIK3CA—salivary gland cancer	1.59e-05	2.23e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EP300—salivary gland cancer	1.58e-05	2.23e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.58e-05	2.22e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PTEN—salivary gland cancer	1.57e-05	2.22e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PTEN—salivary gland cancer	1.57e-05	2.21e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—PIK3CA—salivary gland cancer	1.56e-05	2.19e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CCND1—salivary gland cancer	1.55e-05	2.18e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CREBBP—salivary gland cancer	1.54e-05	2.17e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CREBBP—salivary gland cancer	1.54e-05	2.17e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	1.54e-05	2.16e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PTEN—salivary gland cancer	1.54e-05	2.16e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—salivary gland cancer	1.54e-05	2.16e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PTEN—salivary gland cancer	1.53e-05	2.16e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—HRAS—salivary gland cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOTCH1—salivary gland cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—CREBBP—salivary gland cancer	1.52e-05	2.14e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EP300—salivary gland cancer	1.5e-05	2.11e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PTEN—salivary gland cancer	1.5e-05	2.11e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAP2K2—salivary gland cancer	1.5e-05	2.11e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PTEN—salivary gland cancer	1.5e-05	2.11e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOTCH1—salivary gland cancer	1.5e-05	2.11e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EP300—salivary gland cancer	1.5e-05	2.11e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—PIK3CA—salivary gland cancer	1.49e-05	2.1e-05	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	1.49e-05	2.09e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCND1—salivary gland cancer	1.48e-05	2.08e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—HRAS—salivary gland cancer	1.47e-05	2.07e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EP300—salivary gland cancer	1.47e-05	2.06e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EP300—salivary gland cancer	1.46e-05	2.06e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HRAS—salivary gland cancer	1.44e-05	2.03e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PIK3CA—salivary gland cancer	1.44e-05	2.03e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NUP62—salivary gland cancer	1.44e-05	2.02e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EP300—salivary gland cancer	1.43e-05	2.01e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—PIK3CA—salivary gland cancer	1.43e-05	2.01e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PTEN—salivary gland cancer	1.43e-05	2.01e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EP300—salivary gland cancer	1.43e-05	2.01e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—VCAN—salivary gland cancer	1.42e-05	2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTEN—salivary gland cancer	1.41e-05	1.99e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AQP1—salivary gland cancer	1.4e-05	1.97e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—CREBBP—salivary gland cancer	1.39e-05	1.96e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CREBBP—salivary gland cancer	1.39e-05	1.95e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HRAS—salivary gland cancer	1.38e-05	1.94e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EP300—salivary gland cancer	1.36e-05	1.92e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CREBBP—salivary gland cancer	1.36e-05	1.91e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EP300—salivary gland cancer	1.35e-05	1.9e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—salivary gland cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—salivary gland cancer	1.32e-05	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—PIK3CA—salivary gland cancer	1.29e-05	1.82e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CREBBP—salivary gland cancer	1.29e-05	1.81e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	1.28e-05	1.81e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—PIK3CA—salivary gland cancer	1.27e-05	1.78e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	1.25e-05	1.76e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PTEN—salivary gland cancer	1.23e-05	1.73e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOTCH1—salivary gland cancer	1.23e-05	1.73e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—salivary gland cancer	1.23e-05	1.72e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	1.22e-05	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PIK3CA—salivary gland cancer	1.21e-05	1.71e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—salivary gland cancer	1.2e-05	1.69e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PIK3CA—salivary gland cancer	1.2e-05	1.69e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PIK3CA—salivary gland cancer	1.2e-05	1.69e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—salivary gland cancer	1.19e-05	1.68e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PIK3CA—salivary gland cancer	1.19e-05	1.68e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTEN—salivary gland cancer	1.18e-05	1.66e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—salivary gland cancer	1.17e-05	1.65e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—salivary gland cancer	1.17e-05	1.65e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EP300—salivary gland cancer	1.17e-05	1.65e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PIK3CA—salivary gland cancer	1.17e-05	1.65e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTEN—salivary gland cancer	1.16e-05	1.63e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—salivary gland cancer	1.14e-05	1.61e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—salivary gland cancer	1.14e-05	1.6e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTEN—salivary gland cancer	1.13e-05	1.6e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EP300—salivary gland cancer	1.13e-05	1.59e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—salivary gland cancer	1.12e-05	1.58e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CREBBP—salivary gland cancer	1.11e-05	1.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—salivary gland cancer	1.11e-05	1.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PIK3CA—salivary gland cancer	1.11e-05	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—salivary gland cancer	1.11e-05	1.56e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NUP62—salivary gland cancer	1.11e-05	1.56e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EP300—salivary gland cancer	1.11e-05	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PIK3CA—salivary gland cancer	1.11e-05	1.56e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTEN—salivary gland cancer	1.1e-05	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—salivary gland cancer	1.1e-05	1.55e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTEN—salivary gland cancer	1.1e-05	1.55e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—VCAN—salivary gland cancer	1.1e-05	1.55e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTEN—salivary gland cancer	1.09e-05	1.53e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—salivary gland cancer	1.08e-05	1.53e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—salivary gland cancer	1.08e-05	1.52e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EP300—salivary gland cancer	1.08e-05	1.52e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—salivary gland cancer	1.08e-05	1.52e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—salivary gland cancer	1.06e-05	1.49e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—salivary gland cancer	1.06e-05	1.49e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EP300—salivary gland cancer	1.05e-05	1.48e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—salivary gland cancer	1.05e-05	1.48e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EP300—salivary gland cancer	1.05e-05	1.48e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—EP300—salivary gland cancer	1.03e-05	1.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—salivary gland cancer	1.03e-05	1.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—salivary gland cancer	1.03e-05	1.44e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—salivary gland cancer	1.02e-05	1.44e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—salivary gland cancer	1.02e-05	1.44e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—salivary gland cancer	1.01e-05	1.42e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—salivary gland cancer	1e-05	1.41e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—salivary gland cancer	1e-05	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—salivary gland cancer	1e-05	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—salivary gland cancer	9.98e-06	1.4e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—salivary gland cancer	9.94e-06	1.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—salivary gland cancer	9.9e-06	1.39e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—salivary gland cancer	9.79e-06	1.38e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—salivary gland cancer	9.77e-06	1.38e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—salivary gland cancer	9.75e-06	1.37e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—salivary gland cancer	9.7e-06	1.36e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—salivary gland cancer	9.48e-06	1.33e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—salivary gland cancer	9.44e-06	1.33e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—salivary gland cancer	9.32e-06	1.31e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—salivary gland cancer	9.25e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—salivary gland cancer	9.23e-06	1.3e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—salivary gland cancer	9.21e-06	1.3e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	9.05e-06	1.27e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	8.92e-06	1.26e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—salivary gland cancer	8.78e-06	1.24e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—salivary gland cancer	8.67e-06	1.22e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	8.51e-06	1.2e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—salivary gland cancer	8.34e-06	1.17e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—salivary gland cancer	8.23e-06	1.16e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—salivary gland cancer	8.19e-06	1.15e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—salivary gland cancer	8.07e-06	1.14e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—salivary gland cancer	8.02e-06	1.13e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—salivary gland cancer	8.01e-06	1.13e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CREBBP—salivary gland cancer	8e-06	1.13e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—salivary gland cancer	7.95e-06	1.12e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—salivary gland cancer	7.93e-06	1.12e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—salivary gland cancer	7.77e-06	1.09e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—salivary gland cancer	7.75e-06	1.09e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—salivary gland cancer	7.72e-06	1.09e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—salivary gland cancer	7.66e-06	1.08e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—salivary gland cancer	7.58e-06	1.07e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—salivary gland cancer	7.58e-06	1.07e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—salivary gland cancer	7.52e-06	1.06e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—salivary gland cancer	7.5e-06	1.06e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—salivary gland cancer	7.41e-06	1.04e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—salivary gland cancer	7.19e-06	1.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—salivary gland cancer	7.17e-06	1.01e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—salivary gland cancer	7.01e-06	9.87e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—salivary gland cancer	6.99e-06	9.83e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CREBBP—salivary gland cancer	6.97e-06	9.81e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—salivary gland cancer	6.84e-06	9.63e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—salivary gland cancer	6.76e-06	9.51e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—salivary gland cancer	6.62e-06	9.31e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CREBBP—salivary gland cancer	6.57e-06	9.25e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	6.5e-06	9.14e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—salivary gland cancer	6.46e-06	9.1e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—salivary gland cancer	6.33e-06	8.91e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	6.29e-06	8.86e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—salivary gland cancer	5.71e-06	8.04e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—salivary gland cancer	5.61e-06	7.89e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CREBBP—salivary gland cancer	5.56e-06	7.83e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—salivary gland cancer	5.45e-06	7.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—salivary gland cancer	5.42e-06	7.63e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—salivary gland cancer	5.19e-06	7.3e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—salivary gland cancer	4.98e-06	7.01e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—salivary gland cancer	4.75e-06	6.68e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—salivary gland cancer	4.69e-06	6.6e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—salivary gland cancer	4.47e-06	6.3e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	4.29e-06	6.04e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—salivary gland cancer	4.03e-06	5.67e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—salivary gland cancer	3.97e-06	5.59e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—salivary gland cancer	3.79e-06	5.33e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	3.51e-06	4.94e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—salivary gland cancer	3.31e-06	4.66e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—salivary gland cancer	3.07e-06	4.32e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—salivary gland cancer	2.92e-06	4.12e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—salivary gland cancer	2.8e-06	3.95e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	2.16e-06	3.05e-06	CbGpPWpGaD
